Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Meningioma 1Glioblastoma 1Frailty 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × Photons × Clear all
NCT02179086 2026-01-14

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2 Active not recruiting
606 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡